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Abstract
Objectives. We aimed to provide insights into the aetiology of granulomatosis with polyangiitis (GPA), by
conducting a large casecontrol study using a general population-based, prospectively collected database
of healthcare records.
Methods. We compared all incident cases of GPA in the Clinical Practice Research Datalink 19902014,
with up to 10 age-, sex- and general practice-matched controls. We identified potential risk factors,
recorded numbers of cases and controls exposed to each, and calculated odds ratios (ORs) using con-
ditional logistic regression. Our main analysis excluded data recorded during 1 year before diagnosis, to
prevent early symptoms being mistaken for risk factors.
Results. We identified 757 people with GPA and matched 7546 controls. People with GPA were five times
more likely to have a previous diagnosis of bronchiectasis (OR = 5.1, 95% CI: 2.7, 9.4; P< 0.0001), and
these effects remained stable in diagnoses recorded >5 years prior to diagnosis. People with GPA were
two to three times more likely than controls to have previous diagnoses of autoimmune diseases or
chronic renal impairment, and these effects also remained stable >5 years prior to diagnosis. People
with GPA were more likely to have a diagnosis of pulmonary fibrosis (OR = 5.7, 95% CI: 1.7, 19.5;
P= 0.01) and sinus infections (OR = 2.7, 95% CI: 1.8, 4.2; P<0.0001) recorded in the 3 years before
diagnosis, but not before this. We also found former smoking, some medications and higher socio-eco-
nomic status significantly, but less strongly, associated.
Conclusion. We found novel long-term associations between GPA and pre-existing bronchiectasis and
autoimmune diseases.
Key words: anti-neutrophil cytoplasmic antibody-associated vasculitis, granulomatosis with polyangiitis, risk
factors, aetiology, vasculitis
Rheumatology key messages
. Autoimmune diseases and bronchiectasis are associated with an increased risk of developing granulomatosis
with polyangiitis.
. Sinus infections are associated with an increased risk of developing granulomatosis with polyangiitis for 4 years
before diagnosis.
. Former smoking is associated with an increased risk of developing granulomatosis with polyangiitis compared
with never smoking.
Introduction
Granulomatosis with polyangiitis (GPA) is a rare multisys-
tem condition of unknown aetiology. Much of what we
know about the aetiology of this condition is based on
case reports, case series and small hospital-based
casecontrols studies with retrospective collection of ex-
posures [1]. A large population-based casecontrol study
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of aetiology with prospectively collected exposure data
maximizes information while limiting selection and recall
bias. In this study, we have aimed to compare the fre-
quency of possible aetiological exposures between
cases and population-based controls in a large database
of prospectively collected primary care data.
Methods
Source of data
We used data from the Clinical Practice Research Datalink
(CPRD), which is one of the largest databases of longitu-
dinal medical records from UK primary care. It was estab-
lished in 1987, and now contains anonymized healthcare
records from more than 13 million people and represents
8% of the UK population. Patients are broadly represen-
tative of the UK general population in terms of age, sex
and ethnicity [2]. Records contain diagnostic and clinical
information coded using Read codes [3]. We followed the
CPRD’s recommendations for selecting research-quality
patient records and periods of quality data recording by
including people contributing acceptable quality data in
up-to-standard practices. We used data from all 684 gen-
eral practices contributing data up to January 2015.
Study participants and study design
We included all incident cases of GPA diagnosed between
1 January 1990 and 31 December 2014, identified as
previously described [4]. Briefly, cases were included if
they had a diagnosis of GPA coded in the CPRD or
linked Hospital Episode Statistics (HES) [5] records; for
these people, date of diagnosis was assumed to be the
first recorded code in the CPRD or HES of either GPA
or vasculitis; cases had at least 1 year of disease-free
registration in the CPRD prior to their first code for GPA
or vasculitis to try to exclude prevalent cases. Up to 10
controls were randomly selected for each case, matched
on general practice, sex and within 5 years of age. All
controls also had to be contributing data to the CPRD
continuously for at least 1 year prior to the diagnosis
date of their matched case. The diagnosis date of cases
and the matching date for each control is called the index
date.
Selection of aetiological risk factors
We collated a list of potential risk factors based on previ-
ous research, case reports in the literature and expert
physician opinion. We grouped our potential risk factors
as follows: vascular diseases (hypertension, cardiovascu-
lar disease, gout, type 2 diabetes), autoimmune diseases
(type 1 diabetes, under-/over-active thyroid diseases, RA,
IBD, coeliac disease, vitiligo and Addison’s disease),
chronic lung diseases (chronic obstructive pulmonary dis-
ease, alpha-1 antitrypsin deficiency, pulmonary fibrosis
and bronchiectasis), renal impairment (acute, chronic), in-
fections (upper respiratory tract, lower respiratory tract,
sinus, urinary tract and cellulitis), medications (allopurinol,
carbimazole, levothyroxine, propythiouracil, hydralazine,
minocycline, SSZ and penicillamine—all of which have
been associated with vasculitis), smoking and socio-eco-
nomic status.
Code lists
We used the method described by Dave and Petersen [6]
to compile lists of Read codes for each clinical diagnosis,
or unique CPRD code for each medication. We searched
the description fields of the Read code dictionary and
Product dictionary supplied by the CPRD using a list of
keywords and synonyms and excluding irrelevant codes.
Where possible the resulting code lists were cross-refer-
enced with published code lists available at an online clin-
ical codes repository [7]. Full lists of codes are available
are provided as supplementary data, available at
Rheumatology online.
We extracted smoking records from the GP records,
and categorized smoking status as never, former, current
and unknown. We used the last record before the index
date, and repeated the analysis using the last record prior
to 1 year before the index date.
We used the Index of Multiple Deprivation 2010 (IMD-
10), provided by the Office for National Statistics via a
CPRD-linkage agreement, as a surrogate for socio-eco-
nomic status. This is required because socio-economic
data are poorly recorded in the CPRD itself because
they do not relate directly to patient care [8]. We categor-
ized IMD-10 into quintiles where quintile 1 is the most
deprived, and quintile 5 the least deprived.
Statistical analysis
For the candidate risk factors that were chronic condi-
tions, we recorded the numbers of cases and controls
that had at least one coded record for each of the candi-
date risk factors prior to their index date. We then re-
peated the analyses excluding new diagnoses or newly
prescribed medications 1 year before the index date to
explore whether early symptoms of GPA might be mis-
diagnosed as other illnesses or result in new prescrip-
tions. For chronic conditions that were significantly
associated before 1 year before the index date, we then
repeated this four more times, excluding new records in
the 2, 3, 4 and 5 years before diagnosis to distinguish
long-term risk factors from late-emerging risk factors.
For smoking and IMD-10, which are chronic exposures
but categorical variables, we recorded the numbers of
cases and controls who had each of the categories of
exposure. For infections and acute renal impairment,
which are acute, resolving and possibly recurring epi-
sodes, we recorded the number of cases and controls
that had at least one coded record for each type in time
periods of 1, 01 up to 45 years before diagnosis.
We calculated odds ratios (ORs) comparing risk factors
in cases compared with controls using conditional logistic
regression. Because there are records of delays, often up
to a year, between symptom onset and diagnosis of GPA
[9], our main analysis excluded data from the year before
diagnosis. Statistical analysis was performed using
STATA version 14 (Statacorp, College Station, TX, USA).
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Reporting guidelines
This study is reported following the REporting of studies
Conducted using Observational Routinely-collected health
Data (RECORD) guidelines [10], which are an extension of
the STrengthening the Reporting of OBservational studies
in Epidemiology (STROBE) statement [11], designed spe-
cifically for reporting studies conducted using observational
routinely collected healthcare data.
Ethical approval
Independent Scientific Advisory Committee for Medicines &
Healthcare Products Regulatory Agency (MHRA) database
research approval was obtained for this study on 21 July
2015 (protocol 15_150 R). Patient consent was not required
because no patient-identifiable information was used.
Results
We identified 757 cases of GPA and matched 7546 controls.
The baseline characteristics of cases and controls were
similar: median age (interquartile range) at the index date
was 61 (5070) years in cases and 61 (5071) years in con-
trols, and 44.7% of both cases and controls were female.
Chronic conditions
Pulmonary fibrosis and bronchiectasis were most strongly
associated with GPA (Table 1). In our main results
(excluding new diagnoses in the year before their index
date), people with GPA were 5.7 times more likely than
controls to have a past history of pulmonary fibrosis (OR =
5.7, 95% CI: 1.7, 19.5; P= 0.01) and 5.1 times more likely
to have bronchiectasis (OR = 5.1, 95% CI: 2.7, 9.4;
P< 0.0001). Chronic renal impairment (OR = 2.1, 95%
CI: 1.5, 3.1; P= 0.0001), type 1 diabetes (OR = 2.4, 95%
CI: 1.2, 4.6; P= 0.02), under-/over-active thyroid diseases
(OR = 1.9, 95% CI: 1.4, 2.5; P< 0.0001), RA (OR = 3.3,
95% CI: 2.0, 5.3; P< 0.0001) and IBD (OR = 2.4, 95% CI:
1.4, 4.2; P= 0.004) were all associated with diagnosis of
GPA. The associations were similar, but slightly stronger,
when new diagnoses during the year before the index
date were included. Looking back to 5 years before the
index date (Fig. 1 and supplementary Table S1, available
at Rheumatology online), the risk conferred by bronchiec-
tasis was stable (5 years prior: OR = 5.7, 95% CI: 2.0,
16.1; P= 0.003) but the first cases with pulmonary fibrosis
appeared 23 years before the index date (>2 years prior:
OR = 3.3, 95% CI: 0.3, 32.0; P= 0.4), and the risk rose
rapidly over the 2 years before the index date. The risks
conferred by chronic renal failure, RA, type 1 diabetes,
thyroid disease and IBD remained stable over the period
15 years before the index date, but the ORs tended to
increase in the year prior to diagnosis.
Acute renal impairment
Acute renal impairment occurred in very few cases (n= 8)
or controls (n= 11) >1 year prior to the index date. Acute
renal impairment was recorded more often in cases com-
pared with controls throughout 5 years before diagnosis;
TABLE 1 Chronic conditions and their association with developing granulomatosis with polyangiitis
Diagnosis
Ever before the index date
Main analysis: excluding the last year
before index date
Cases,
n (%)
Controls,
n (%)
Odds ratio
(95% CI) P-value
Cases,
n (%)
Controls,
n (%)
Odds ratio
(95% CI) P-value
Vascular
CVD 74 (9.8) 707 (9.4) 1.1 (0.8, 1.4) 0.7 67 (8.9) 660 (8.8) 1.0 (0.8, 1.3) 0.9
Hypertension 226 (29.9) 2088 (27.7) 1.1 (0.9, 1.4) 0.2 205 (27.1) 1935 (25.6) 1.1 (0.9, 1.3) 0.3
Chronic renal
impairment
77 (10.2) 325 (4.3) 3.3 (2.5, 4.6) <0.0001 49 (6.5) 277 (3.7) 2.1 (1.5, 3.1) 0.0001
Gout 38 (5.0) 284 (3.8) 1.4 (1.0, 2.0) 0.09 33 (4.4) 268 (3.6) 1.2 (0.9, 1.8) 0.3
Type 2 diabetes 56 (7.4) 555 (7.4) 1.0 (0.8, 1.3) 0.96 45 (5.9) 496 (6.6) 0.9 (0.6, 1.2) 0.5
Autoimmune
Type 1 diabetes 12 (1.6) 48 (0.6) 2.5 (1.3, 4.8) 0.009 11 (1.5) 47 (0.6) 2.4 (1.2, 4.6) 0.02
Thyroid disease 83 (11.0) 453 (6.0) 2.0 (1.6, 2.6) <0.0001 74 (9.8) 429 (5.7) 1.9 (1.4, 2.5) <0.0001
RA 40 (5.3) 80 (1.1) 5.3 (3.6, 7.8) <0.0001 23 (3.0) 72 (1.0) 3.3 (2.0, 5.3) <0.0001
IBD 18 (2.4) 69 (0.9) 2.6 (1.6, 4.4) 0.001 16 (2.1) 66 (0.9) 2.4 (1.4, 4.2) 0.004
Coeliac disease 2 (0.3) 19 (0.3) 1.1 (0.2, 4.5) 0.9 2 (0.3) 18 (0.3) 1.1 (0.3, 4.8) 0.9
Vitiligo 1 (0.1) 15 (0.2) 0.7 (0.1, 5.1) 0.7 1 (0.1) 14 (0.2) 0.7 (0.1, 5.5) 0.7
Addison’s disease 0 1 (0.01)
Chronic lung disease
COPD 41 (5.4) 273 (3.6) 1.5 (1.1, 2.2) 0.02 29 (3.8) 237 (3.2) 1.2 (0.8, 1.8) 0.3
Alpha-1 ATD 0 1 (0.01)
Pulmonary fibrosis 8 (1.1) 10 (0.1) 8.0 (3.2, 20.3) 0.0001 4 (0.5) 7 (0.1) 5.7 (1.7, 19.5) 0.01
Bronchiectasis 20 (2.6) 34 (0.5) 6.0 (3.4, 10.6) <0.0001 15 (2.0) 30 (0.4) 5.1 (2.7, 9.4) <0.0001
CVD: cardiovascular disease; COPD: chronic obstructive pulmonary disease; alpha-1 ATD: alpha-1 antitrypsin deficiency.
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however, the results were not statistically significant
(Table 2).
Infections
Sinus infection was the infection most strongly associated
with developing GPA, with an OR of 2.7 (95% CI: 1.8, 4.2;
P< 0.0001) 12 years prior to the index date (Table 2). The
ORs remained elevated until 4 years before the index
date. Upper and lower respiratory tract infections were
also less strongly but significantly associated during 12
years prior to the index date (OR = 1.7, 95% CI: 1.3, 2.3;
P= 0.0004; and OR = 1.4, 95% CI: 1.0, 2.1; P= 0.05,
respectively), but not before this time. There was no
association between urinary tract infection or cellulitis
and developing GPA.
Smoking
Former smoking was associated with an increased risk of
developing GPA compared with never smokers (OR = 1.5,
95% CI: 1.2, 1.8; P< 0.001) (Table 3). Current smoking
was marginally associated with a decreased risk of de-
veloping GPA compared with never smokers (OR = 0.8,
95% CI: 0.7, 1.0; P= 0.077).
Medications
SSZ was the medication most strongly associated with
developing GPA, with an OR 1 year prior to the index
date of 3.0 (95% CI: 1.4, 6.4; P= 0.01), and an OR 5
years prior of 2.5 (95% CI: 0.9, 6.8; P= 0.1) (Table 4; sup-
plementary Fig. S1 and Table S2, available at
Rheumatology online). The estimated risk conferred by
the medications used for thyroid disease were around
two and remained stable throughout the 5 years prior to
the index date. Allopurinol (OR = 1.8, 95% CI: 1.2, 2.8;
P= 0.01) was also associated with developing GPA.
Penicillamine, propylthiouracil and hydralazine were pre-
scribed too rarely for us to be able to comment with con-
fidence on any possible association.
Socio-economic status
IMD-10 data were available for the 5573 (67.1%) of our
study population who were registered at GP practices in
England. There was a weak association between decreas-
ing socio-economic deprivation and increased risk of GPA
(Table 5). The least deprived IMD-10 quintile were esti-
mated to be 30% more likely than the most deprived to
develop GPA (OR = 1.3, 95% CI: 0.9, 1.9; P-trend 0.02).
Discussion
Main results
To our knowledge this is the largest casecontrol study of
the aetiology of GPA. We found that people with GPA
were two to three times more likely than population-
based controls to have a previous diagnosis of an auto-
immune disease or chronic renal impairment, and these
effects remained stable when we looked at diagnoses re-
corded >5 years prior to diagnosis. People with GPA were
also more likely to have pulmonary fibrosis and sinus in-
fections at diagnosis, but these effects appeared in the 3
years prior to diagnosis, and were either late risk factors
or early symptoms of GPA. Intriguingly, we found that
people with GPA were five times more likely than popula-
tion-based controls to have a previous diagnosis of bron-
chiectasis, and these effects remained stable when we
looked at diagnoses recorded >5 years prior to diagnosis.
FIG. 1 Chronic conditions: association with developing granulomatosis with polyangiitis
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To our knowledge, an association between bronchiectasis
and GPA has not previously been reported.
Strengths and limitations
The main strengths of our study are the large number of
people in the study population, and the long follow-up
period. In addition, the population-based nature of our
case ascertainment should include people who are repre-
sentative of the full spectrum of people with GPA, in con-
trast to the selected cohorts included in studies in tertiary
referral centres or clinical trials [12]. Using prospectively
collected data from an electronic health record limits
recall bias, which is a major consideration in studies of
aetiology. The main limitations of our study include lack
TABLE 2 Acute, resolving illnesses and their association with developing granulomatosis with polyangiitis
Years before index date Cases, n (%) Controls, n (%) Odds ratio (95% CI) P-value
Acute renal impairment
01 35 (4.6) 2 (0.03) 175.0 (42.1, 727.6) <0.0001
12 2 (0.3) 5 (0.07) 4.8 (0.9, 26.4) 0.1
23 1 (0.2) 3 (0.05) 4.8 (0.4, 53.3) 0.3
34 0 3 (0.05)  
45 5 (0.1) 0  
Sinus infection
01 110 (14.5) 116 (1.5) 11.2 (8.5, 14.9) <0.0001
12 28 (4.1) 111 (1.6) 2.7 (1.8, 4.2) <0.0001
23 20 (3.2) 86 (1.4) 2.5 (1.5, 4.1) 0.001
34 16 (2.8) 86 (1.5) 1.9 (1.1, 3.2) 0.04
45 12 (2.3) 86 (1.7) 1.4 (0.7, 2.6) 0.3
Upper respiratory tract infection
01 111 (14.7) 419 (5.6) 3.1 (2.4, 3.9) <0.0001
12 64 (9.5) 397 (5.8) 1.7 (1.3, 2.3) 0.0004
23 37 (6.0) 385 (6.2) 1.0 (0.7, 1.4) 0.9
34 36 (6.4) 323 (5.7) 1.1 (0, 8, 1.6) 0.6
45 43 (8.3) 318 (6.3) 1.3 (0.9, 1.9) 0.1
Lower respiratory tract infection
01 104 (13.7) 331 (4.4) 3.7 (2.9, 4.7) <0.0001
12 39 (5.8) 284 (4.2) 1.4 (1.0, 2.1) 0.05
23 23 (3.7) 234 (3.7) 1.0 (0.6, 1.5) 0.9
34 28 (5.0) 209 (3.7) 1.4 (0.9, 2.1) 0.1
45 17 (3.3) 189 (3.7) 0.9 (0.5, 1.5) 0.7
Urinary tract infection
01 35 (4.6) 204 (2.7) 1.8 (1.2, 2.6) 0.004
12 20 (3.0) 201 (2.9) 1.0 (0.6, 1.6) 1.0
23 16 (2.6) 163 (2.6) 1.0 (0.6, 1.7) 1.0
34 15 (2.7) 150 (2.7) 1.0 (0.6, 1.7) 1.0
45 14 (2.7) 117 (2.3) 1.1 (0.6, 1.9) 0.8
Cellulitis
01 29 (3.8) 98 (1.3) 3.1 (2.0, 4.7) <0.001
12 8 (1.2) 97 (1.4) 0.9 (0.4, 1.8) 0.7
23 9 (1.5) 67 (1.1) 1.4 (0.7, 2.9) 0.3
34 5 (0.9) 69 (1.2) 0.7 (0.3, 1.8) 0.4
45 8 (1.5) 54 (1.1) 1.4 (0.7, 2.9) 0.4
TABLE 3 Smoking and its association with developing granulomatosis with polyangiitis
Diagnosis
Last record prior to the index date Last record prior to 1 year before the index date
Cases,
n (%)
Controls,
n (%)
Odds ratio
(95% CI) P-value
Cases,
n (%)
Controls,
n (%)
Odds ratio
(95% CI) P-value
Smoking status
Never 349 (46.1) 33505 (46.5) 1 336 (44.4) 3, 415 (45.3) 1
Former 172 (22.7) 1241 (16.5) 1.5 (1.2, 1.8) <0.001 149 (19.7) 1, 074 (14.2) 1.5 (1.2, 1.8) <0.001
Current 172 (22.7) 2052 (27.2) 0.8 (0.7, 1.0) 0.037 186 (24.6) 2, 177 (28.9) 0.8 (0.7, 1.0) 0.077
Unknown 64 (8.5) 744 (9.9) 0.8 (0.6, 1.1) 0.12 86 (11.4) 880 (11.7) 0.9 (0.7, 1.3) 0.68
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of power for the risk factors that occur infrequently in con-
trols, and the possibility of misclassification of diagnoses
and other exposures in the CPRD. Previous studies have
demonstrated the high (90%) positive predictive value of
the recording of a diagnosis of GPA [13], and similarly high
validity of records of other chronic medical diagnoses,
infections and prescription records [1416] in the CPRD.
Unfortunately, it is no longer possible to check these in
our sample using anonymized hospital correspondence
from the CPRD due to a tightening of their procedures
to protect confidentiality. The quality of smoking data is
enhanced by the Quality and Outcomes framework, which
provides an incentive payment to English GPs for record-
ing key data items. We have ensured good quality of
socio-economic data by using the IMD-10, the official
measure of relative deprivation for neighbourhoods in
England; however, these data are only available for
people who consent to this linkage and who are registered
at GP practices in England, comprising 67% of our data-
set. Despite this theoretical limitation, we found a small
but statistically significant increased risk of developing
GPA among the least deprived people compared with
the most deprived group.
How our study fits in with the other literature
Bronchiectasis was the most strongly associated long-
term risk factor in our study. Bronchiectasis is already
known to be associated with other autoimmune diseases,
particularly RA [17, 18]. Bronchiectasis has previously
been reported in two retrospective single centre studies
from France and Japan to be associated with microscopic
polyangiitis and anti-myeloperoxidase ANCA-associated
vasculitis (AAV) [19, 20], and there are reports of
people with bronchiectasis and an atypical p-ANCA dir-
ected against bactericidal/permeability-increasing protein
ANCA, often after Pseudomonas aeruginosa infection of
the lungs [2123]. This is the first study we are aware of
reporting a long-term association between bronchiectasis
and GPA. Three possible reasons for the association exist:
that bronchiectasis contributes to causing GPA, that they
share aetiological factors or that they are both manifest-
ations of the same disease spectrum. It is particularly intri-
guing because the aetiology of bronchiectasis is
unknown, and there are some case reports of bronchiec-
tasis resolving with immunosuppression [24, 25].
The association with pulmonary fibrosis is interesting,
because it has previously been associated with micro-
scopic polyangiitis, but not specifically with GPA. This as-
sociation in the 13 years before diagnosis could be due
to any of the same three reasons as bronchiectasis, but
because it is a late association it is more likely to be a
manifestation of the same disease. The more common
chronic lung disease, chronic obstructive pulmonary dis-
ease (including emphysema), on the other hand, did not
show an association with developing GPA, which is
possibly due to a protective effect of smoking. Alpha-1
TABLE 4 Medications and their association with developing granulomatosis with polyangiitis
Drug
Ever before the index date Excluding the last year before the index date
Cases,
n (%)
Controls,
n (%)
Odds ratio
(95% CI) P-value
Cases,
n (%)
Controls,
n (%)
Odds ratio
(95% CI) P-value
Allopurinol 30 (4.0) 163 (2.2) 1.9 (1.3, 2.9) 0.0032 26 (3.4) 147 (2.0) 1.8 (1.2, 2.8) 0.01
Carbimazole 9 (1.2) 46 (0.6) 2.0 (1.0, 4.1) 0.08 8 (1.1) 43 (0.6) 1.9 (0.9, 4.1) 0.13
Levothyroxine 71 (9.4) 353 (4.7) 2.2 (1.7, 2.9) <0.0001 62 (8.2) 332 (4.4) 2.0 (1.5, 2.7) <0.0001
Propylthiouracil 1 (0.1) 7 (0.1) 1.4 (0.2, 11.5) 0.76 1 (0.1) 5 (0.1) 2.0 (0.2, 16.8) 0.57
Hydralazine 2 (0.3) 9 (0.1) 2.3 (0.5, 10.8) 0.34 2 (0.3) 8 (0.1) 2.6 (0.5, 12.5) 0.29
Minocycline 17 (2.3) 94 (1.3) 1.8 (1.1, 3.1) 0.03 14 (1.9) 90 (1.2) 1.6 (0.9, 2.8) 0.1
SSZ 14 (1.9) 31 (0.4) 4.6 (2.4, 8.6) <0.0001 9 (1.2) 30 (0.4) 3.0 (1.4, 6.4) 0.01
Penicillamine 4 (0.5) 10 (0.1) 4.0 (1.3, 12.8) 0.04 4 (0.5) 10 (0.1) 4.0 (1.3, 12.8) 0.04
TABLE 5 Socio-economic status and its association with developing granulomatosis with polyangiitis
IMD-10 quintile
Ever before the index date
Cases,
n (%)
Controls,
n (%)
Odds ratio (95% CI)—
categorical variable
Odds ratio (95% CI)—
continuous variable P-valuea
Quintile 1 (most deprived) 113 (22.2) 1220 (24.1) 1 1.1 (1.0, 1.2) 0.02
Quintile 2 114 (22.4) 1303 (25.7) 0.96 (0.7, 1.3)
Quintile 3 114 (22.4) 1041 (20.6) 1.3 (0.9, 1.8)
Quintile 4 102 (20.0) 854 (16.9) 1.5 (1.0, 2.1)
Quintile 5 (least deprived) 66 (13.0) 646 (12.8) 1.3 (0.9, 1.9)
aP-value for trend from the likelihood ratio test. IMD-10: Index of Multiple Deprivation 2010.
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anti-trypsin deficiency, which has previously been asso-
ciated [26], was too rare in our cohort for us to comment.
We found that type 1 diabetes, under-/over-active thy-
roid diseases, RA and IBD occurred two to three times
more commonly in cases than in the general population
controls. Coeliac disease, vitiligo and Addison’s disease
occurred in zero to two cases each only, so we have in-
sufficient power to comment in these conditions.
Autoimmune diseases are well-recognized to cluster in
individuals and families [2729]; however, this is one of
the first studies we are aware of reporting the association
of GPA with several other autoimmune diseases. Lionaki
et al. conducted a casecontrol study of 158 cases of
AAV, and found a history of thyroid disease to be more
common in cases than in age- and sex-matched controls
(OR = 3.7, 95% CI: 1.5, 9.2; P= 0.005) [30]. Other evi-
dence comes from case series: there have been reports
of 6 cases where AAV occurred after a diagnosis of RA
[31], 7 cases of co-existence of primary SS and AAV [32]
and 35 cases of co-existence of scleroderma and AAV
[33]. It seems likely that the finding of clustering of auto-
immune diseases in individuals [29] is contributed to by
shared genetic susceptibility loci at immune regulatory
genes (HLA [34], CTLA-4 [35, 36], PTPN22 [37] and
CD40 [38]) [39, 40]. Other evidence pointing to shared
mechanisms of immune dysregulation in autoimmune
conditions include that atypical ANCAs also occur fre-
quently in IBD, RA and thyroid disease [41].
Our study did not provide evidence of infections as
long-term risk factors for GPA, with the exception of
sinus infections. Sinus infections occurred more than
twice as commonly in people with GPA compared with
controls up to 4 years before diagnosis. All types of infec-
tion were significantly associated only in the last year
before the index date, and it may be that the early symp-
toms of GPA were mistaken for infections, or that the con-
cept of infections acting as a stochastic event that triggers
the sudden flare of GPA may be true. In our dataset we
were unable to specifically identify Staphylococcus aureus
infections, so we are unable to comment on the previously
reported association [42].
Chronic renal impairment, and possibly acute renal im-
pairment, were also, surprisingly, more frequently re-
corded before 1 year prior to diagnosis in people with
GPA compared with controls. This association has not,
to our knowledge, been reported before. For chronic
renal impairment, the size of the effect remained signifi-
cant at least 5 years before the index date. Other diseases
associated with vascular damage, such as hypertension,
type 2 diabetes, cardio-vascular disease and gout, were
not increased in people with GPA, although they have
been previously reported as being more common after
diagnosis [43]. It therefore does not seem that vascular
damage triggers GPA, but raises the possibility of minor
flares of renal vasculitis causing renal damage but not
fulminant vasculitis, over at least 5 years prior to diagnosis
in up to 35% of cases.
Several drugs have previously been associated with
GPA [1]. In our study we have attempted to quantify the
effect of previously implicated drugs compared with the
effect of having the prescribing indication, by presenting,
for example, the ORs for gout and allopurinol. Allopurinol
appears to confer a risk of developing GPA that is greater
than the risk conferred by its indication. However, SSZ
conferred a similar risk to that of RA itself, and carbimazole
and levothyroxine conferred a risk similar to thyroid dis-
ease itself. It should be noted that the number of cases
prescribed penicillamine, propylthiouracil and hydralazine
were so small that these results should be interpreted cau-
tiously. We were unable to include thioridazine as there
were no cases, and levamisole (used to adulterate cocaine)
because we were unable to quantify its use.
Former smoking was associated with developing GPA,
which is a further novel finding of our study. We also found
that current smoking was possibly slightly protective, as
has been shown previously in a small study comparing the
smoking habits at diagnosis of AAV in 197 German
people, with the smoking prevalence in the German popu-
lation [44]. This could be due to the immunosuppressive
effect of smoking, which is caused mainly by the inhal-
ation of nicotine [45]. Few studies have been reported of
the effects on the immune system of stopping smoking. A
similar association with former smoking has been found in
sarcoid [46], which is also another granulomatous dis-
ease. However, this line of thought does not extend to
IBD, where Crohn’s disease, which is granulomatous, is
more frequent in smokers whereas in ulcerative colitis,
which is not granulomatous, smoking is protective [47].
This is the first report of socio-economic deprivation in
GPA, suggesting that it is weakly associated with higher
socio-economic status. However, this effect may be exag-
gerated or even caused by some people with GPA re-
maining undiagnosed if these are particularly those with
lower socio-economic status who may be less successful
at getting the often difficult-to-obtain diagnosis.
Clinical implications and conclusion
Our study found a novel association between pre-existing
bronchiectasis and the development of GPA, and con-
firmed previously described associations with autoim-
mune diseases, renal impairment, pulmonary fibrosis,
sinus infection and previous smoking.
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